Latest NeuroVive Pharmaceutical AB Stories
LUND, Sweden, March 25, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th. The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in...
LUND, Sweden, March 22, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion(R) (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction. The CIRCUS trial (does Cyclosporine ImpRove Clinical...
LUND, Sweden, March 18, 2013 /PRNewswire/ -- NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive. Anna Malm Bernsten has more than 25 years of international marketing and sales experience in the healthcare industry. She was until...
LUND, Sweden, March 11, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. The acquisition of these assets is important strategically as it will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of the...
LUND, Sweden, February 1, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, is pleased to announce the appointment of Jan Nilsson as Chief Operating Officer (COO). Jan will oversee the day-to-day operations of the Company and support the planned commercialisation of CicloMulsion(R) and NeuroSTAT(R), NeuroVive's leading products for the treatment of acute cardiovascular and neurological conditions through mitochondrial protection. Jan has over 30...
LUND, Sweden, December 3, 2012 /PRNewswire/ -- NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion(R) in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion(R) demonstrates bioequivalence and improved tolerability when compared with Sandimmune(R) Injection. The mitochondrial medicine company NeuroVive Pharmaceutical today announces...
HONG KONG, Nov. 20, 2012 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug franchise in China's prescription market, is pleased to announce that it has entered into a collaboration agreement with NeuroVive Pharmaceutical AB ("NeuroVive"), a leading international mitochondrial pharmaceutical development company, to...
BEIJING and LUND, Sweden, November 20, 2012 /PRNewswire/ -- NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. for the development and commercialisation in China of NeuroVive's most clinically advanced products CicloMulsion(R) and NeuroSTAT(R). Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China and the market leader in the fast-growing Chinese...
Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue LUND, Sweden, April 19 /PRNewswire/ - NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM )cremophor-free IV cyclosporine formulation is used...
